Daily Chart

Pfizer Inc. (PFE) Financial News - Merck Options Are Most Bearish Since 2006 Before Earnings

Pfizer Inc. (PFE)

Merck Options Are Most Bearish Since 2006 Before Earnings

Quote: Pfizer Inc. (PFE) CEO who began his job a month before Frazier, has his New York-based company pursuing the sale or spinoff of at least two businesses as it faces patent losses on the cholesterol treatment Lipitor, the world’s best-selling drug, in November. No such plan has come from Frazier, who has only said he won’t rule out unit sales as he faces lost revenue next year from Singulair, with $5 billion in 2010 sales. Whitehouse StationNew Jersey, reports earnings tomorrow. Its puts cost 42 percent more than calls, near the 49 percent level reached July 25. That figure was the most since October 2006, Bloomberg data show. New York, said in a telephone interview. “People are waiting to see what Ken Frazier views the future of Merck as.” Merck shares have declined 3.1 percent this year while Pfizer’s shares jumped 11 percent. The Standard & Poor’s 500 Index advanced 3.4 percent while health-care stocks in the benchmark measure of U.S. shares climbed 8.7 percent. Three Options Merck has three opportunities to improve performance, Polischuk said. It could sell some divisions or older products as Pfizer is doing, it could acquire more companies, or it could focus on research over the long term and hope that its pipeline comes through despite recent stumbles, Polischuk said. Frazier “just hasn’t tipped his hand yet on which it is going to be,” he said. Steven Campanini, a spokesman for Merck, declined to comment. Seamus Fernandez, an analyst at Leerink Swann & Co. Pfizer’s animal health unit had sales last year of $3.48 billion. Singulair next year will follow Merck’s Cozaar and Hyzaar blood pressure medicines, which went off-patent in 2010, resulting in a 57 percent sales drop in the fourth quarter. Drug Pipeline This year, Merck has reported setbacks in its experimental drug pipeline. In January, it halted a trial of the bloodthinner vorapa...
Open whole article (external link)

Other Financial and Stock Market News concerning Pfizer Inc.

Pfizer Inc. Stock Summary

Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. Its Pharmaceutical segment offers Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; Lyrica for neuropathic pain; Geodon/Zeldox, a psychotropic agent; and Aricept for Alzheimer?s disease. It also provides Celebrex for arthritis pain, and inflammation and acute pain; Vfend for esophageal candidiasis and blood stream infections; Zyvox for bacterial infections; and Selzentry/Celsentri for adults infected with only CCR5-tropic HIV-1 detectable. In addition, this segment provides Viagra for erectile dysfunction; Detrol and Toviaz for overactive bladder; Camptosar for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; and Genotropin for growth disorders. The company?s Animal Health segment offers parasiticides, anti-inflammatories, antibiotics, vaccines, antiemetics, and anti-obesity agents. It also provides Revolution/Stronghold for dogs and cats; Rimadyl for pain and inflammation associated with canine osteoarthritis and soft tissue orthopedic surgery; Clavamox/Synulox for skin and soft tissue infections; RespiSureOne/StellamuneOne to prevent pneumonia in swine; Bovi-Shield Gold for reproductive and respiratory protection; Dectomax, an injectable and pour-on formulations; Draxxin, an antibiotic for infections in cattle and swine; and Excede to treat infections in dairy cows, beef cattle, and swine. Pfizer Inc. also involves in contract manufacturing and bulk pharmaceutical chemicals businesses. It serves doctors, nurse practitioners, physician assistants, pharmacists, hospitals, pharmacy benefit managers, managed care organizations, and government agencies. The company was founded in 1849 and is headquartered in New York, New York.
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.